GEN Exclusives

More »

GEN News Highlights

More »
Oct 7, 2009

Gen-Probe to Pay $60M in Prodesse Buyout

  • Gen-Probe plans on acquiring Prodesse for approximately $60 million in cash. Achievement of certain financial and regulatory milestones in the next two years will trigger an additional $25 million payment. Prodesse develops molecular diagnostic reagents for a variety of infectious disease applications.

    In connection with the acquisition, Gen-Probe and Prodesse have signed an agreement under which Gen-Probe's sales representatives in the U.S., Canada, and Europe will begin co-promoting Prodesse's assays later this month. Gen-Probe's initial expectation is that the acquisition will add approximately $0.05 to the its 2010 EPS, based on approximately $15 million in total revenues. Prodesse sells three FDA 510(k) cleared products in the U.S. and two additional CE-marked products in Europe.

    The company's assays can be used in conjunction with various nucleic acid extraction and real-time PCR platforms including Cepheid's SmartCycler® II System. Prodesse's ProFlu+™ test was approved by the FDA in January 2008 for the detection and discrimination of influenza A virus, influenza B virus, and respiratory syncytial virus. It is the only commercially available, FDA-cleared molecular test for these respiratory viruses that uses real-time PCR technology, according to the companies.

    Prodesse also sells FDA-approved, real-time PCR assays for the clinical diagnosis of Clostridium difficile and human metapneumovirus, a common cause of lower respiratory infection in children.


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »